Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of ONO-5163 (etelcalcetide) in secondary hyperparathyroidism under maintenance dialysis
jRCT2080221933Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Oct 2012
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2 trial of etelcalcetide in secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD) (2 arms), sponsored by Ono Pharmaceutical. Primary endpoint: Safety and tolerability of etelcalcetide single and multiple IV doses. Started Oct 2012; status: completed.
02
Drugs
etelcalcetide
03
Conditions
secondary hyperparathyroidism (SHPT)chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2080221933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221933.